HIV-Protease Inhibitors and Drug Resistance in Kaposi's Sarcoma Cells
Author Information
Author(s): Lucia M B, Anu R, Handley M, Gillet J-P, Wu C-P, De Donatis G M, Cauda R, Gottesman M M
Primary Institution: National Cancer Institute, NIH
Hypothesis
Can HIV-protease inhibitors induce multidrug resistance in Kaposi's sarcoma cells through increased expression of ABCB1?
Conclusion
HIV-protease inhibitors select for increased ABCB1 expression in Kaposi's sarcoma cells, leading to multidrug resistance.
Supporting Evidence
- Chronic treatment with HIV-protease inhibitors increased resistance to doxorubicin in Kaposi's sarcoma cells.
- ABCB1 expression levels correlated with the degree of drug resistance observed.
- Co-treatment with doxorubicin and HIV-protease inhibitors resulted in a synergistic increase in resistance.
Takeaway
This study found that certain HIV drugs can make cancer cells more resistant to treatment by changing how they handle medicines.
Methodology
Kaposi's sarcoma cells were treated with HIV-protease inhibitors and doxorubicin, and ABCB1 expression was measured using qRT-PCR and western blotting.
Limitations
The study primarily focuses on in vitro results, which may not fully represent in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website